<DOC>
	<DOCNO>NCT00667446</DOCNO>
	<brief_summary>The purpose extension study determine leuprolide acetate ( 11.25 mg 30 mg ) safe treat child Central Precocious Puberty long period time ( 36 month ) .</brief_summary>
	<brief_title>Safety Extension Study Of Leuprolide Acetate ( Lupron Depot ) In The Treatment Of Central Precocious Puberty</brief_title>
	<detailed_description>This study include 36-month Study Drug Treatment Period ( 3-month treatment cycle ) , Safety Follow-up Period ( 12 week follow Month 36 visit ) . Participants receive total twelve injection treatment receive lead-in study , L-CP07-167 ( NCT00635817 ) either leuprolide acetate 11.25 mg 30 mg depot formulation . Each injection administer 3 month apart 36 month treatment . Study visit occur Day 1 , Months 3 , 6 , 9 , 12 , 15 , 18 , 21 , 24 , 27 , 30 33 ( 1st 12th leuprolide acetate depot injection , respectively ) , Month 36 , 12 week later Safety Follow-up Visit .</detailed_description>
	<mesh_term>Puberty , Precocious</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Subject complete Treatment Period leadin study , LCP07167 ( NCT00635817 ) , document luteinizing hormone suppression evidence peakstimulated luteinizing hormone &lt; 4 mIU/mL Month 6 study visit leadin study . Demonstrated suppression physical sign puberty Month 6 leadin study . Subject expect receive least 12 month therapy treat Central Precocious Puberty study entry . In general good health uncontrolled , clinically significant disease would interfere bone maturation mask objective protocol assess investigator . Incomplete precocious puberty , peripheral precocious puberty evidence abnormal pituitary , hypothalamic , adrenal , thyroid gonadal function ( premature secretion gonadotropin ) adequately control , unstable intracranial tumor except hamartoma . Bone age ≥14 year girls ≥15 year boys ( base Month 6 lead study , LCP07167 , radiographic result ) . Has abnormal laboratory value suggest clinically significant underlying disease condition . Chronic illness require treatment may interfere growth , ie , chronic steroid use , renal failure , moderate severe scoliosis . Current therapy medroxyprogesterone acetate . Current therapy growth hormone . Current therapy insulinlike growth factor1 ( IGF1 ) . Current use estrogen preparation . Any concomitant medical condition , opinion investigator , may expose subject unacceptable level safety risk affect subject compliance . Subject positive pregnancy test .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>GnRH analog</keyword>
	<keyword>Luteinizing hormone ( LH )</keyword>
	<keyword>Gonadotrophin-releasing hormone agonist ( GnRHa )</keyword>
	<keyword>Suppression LH</keyword>
	<keyword>Gonadotrophin-releasing hormone ( GnRH )</keyword>
	<keyword>CPP</keyword>
	<keyword>Leuprolide acetate</keyword>
	<keyword>Central Precocious Puberty</keyword>
	<keyword>Depot formulation</keyword>
	<keyword>Lupron</keyword>
	<keyword>Tanner stag</keyword>
	<keyword>Pediatrics</keyword>
</DOC>